<DOC>
	<DOC>NCT00747123</DOC>
	<brief_summary>Multi-center, randomized, multiple-dose study to evaluate the safety, tolerability and efficacy of ACE-011 in patients with osteolytic lesions of multiple myeloma.</brief_summary>
	<brief_title>A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Key Patient at least 18 years of age with stage II or III multiple myeloma One or more lytic bone lesions If currently receiving bisphosphonate therapy, have been on a stable dose for ≥ 2 months before dosing day 1 or must not have received bisphosphonates within 2 months of dosing day 1 If patient has undergone previous autologous or allogenic hematopoietic stem cell transplantation (HSCT), they must be stable (in the opinion of the investigator) and be a minimum of 6 months since HSCT Has planned HSCT for the duration of the study Has moles or lesions that are currently undiagnosed, but are suspect for malignancy Has an underlying condition that may result in abnormal bone metabolism other than cancer related bone lesions, such as a history of hyperparathyroidism, hypoparathyroidism, hypocalcemia, rheumatoid arthritis, myeloproliferative disorder, gout, Paget's disease of the bone, or osteomalacia; patients with a diagnosis of osteoporosis prior to multiple myeloma diagnosis are eligible to participate. Key Known underlying condition that may result in abnormal bone metabolism other than cancer related bone lesions History of polyneuropathy ≥ grade 3 Patients with plasma cell leukemia Planned stem cell transplant (HSCT) or radiation for the duration of the study Skeletal related event within 2 weeks of study enrollment Has received erythropoiesisstimulating agents (ESAs) within the last 21 days or is planned to receive ESAs during the course of the study Has received antimyeloma therapy within the last 21 days Is scheduled to receive local radiation to bone during the course of the study Has taken estrogen, androgen, anabolic steroids, calcitonin or other boneactive drugs within 4 months of study enrollment Woman of childbearing potential (not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>